ClinicalTrials.gg
Active, not recruitingNCT07632794AutoClipUpdated Jun 8, 2026

Artificial Intelligence Assisting Transcatheter Mitral Edge-to-Edge Repair

An observational study in Mitral Regurgitation, sponsored by Mi Chen. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Mi Chen · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 63 studies in Mitral Valve Insufficiency with a site in Italy — 20 open to participants now, 28 under way, none of them phase 3. Mitral Valve Insufficiency · Italy.

Planned enrollment
2nd of 33
1,500 · median 200
Started
2025
with 5 others
Observational
33 of 63
11 open now
Primary completion
2026-12
later than 14 of 27 live
Registered
63rd of 63
by date

Among the 63 studies in Mitral Valve Insufficiency with a site in Italy, this one is the 2nd largest by planned enrollment of the 33 observational ones that give a count, is one of 6 that started in 2025, is one of 33 observational ones, reaches primary completion later than 14 of the 27 other live ones, and was the 63rd registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

20 of the 63 studies in Mitral Valve Insufficiency with a site in Italy are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Mitral Valve Insufficiency with a site in Italy, or all of them as a file.
02

Study summary

This multicenter, retrospective study develops and validates artificial intelligence (AI)-based semantic segmentation algorithms for intraprocedural transesophageal echocardiography (TEE) during Transcatheter Mitral Edge-to-Edge Repair (TEER). Using pooled imaging data from multiple high-volume structural heart centers, the study aims to automate recognition of mitral leaflets and MitraClip components, measure leaflet insertion length in real time, and display clip position and orientation. Algorithm performance will be benchmarked against expert manual annotations.

Read the detailed description

Transcatheter Mitral Edge-to-Edge Repair (TEER) with the MitraClip device is an established minimally invasive treatment for patients with severe mitral regurgitation who are at high surgical risk. The success of TEER relies heavily on real-time transesophageal echocardiography (TEE) to guide precise clip positioning and leaflet capture. However, intraoperative image interpretation remains highly dependent on operator experience, and variability in image quality, patient anatomy, and the dynamic nature of cardiac structures continue to challenge procedural standardization across centers.

This multicenter, retrospective imaging study evaluates whether artificial intelligence (AI)-based semantic segmentation can automate the recognition of mitral valve anatomy and MitraClip device components on intraprocedural TEE images. Previously acquired TEE imaging from adult patients who underwent TEER at multiple participating high-volume structural heart centers will be pooled and analyzed. All data are derived from routine clinical care, and only patients with appropriate consent for research use of their clinical and imaging data are included.

The study has three objectives: (1) to develop deep learning models that automatically segment the anterior and posterior mitral leaflets and the MitraClip grippers and arms; (2) to automate real-time measurement of leaflet insertion length during the grasping process; and (3) to integrate three-dimensional imaging with intelligent tracking to display clip position and orientation. By drawing on a multicenter dataset, the study aims to improve the generalizability and robustness of the resulting models across diverse imaging environments, operator practices, and patient anatomies. Algorithm performance will be benchmarked against expert manual annotations using established image segmentation metrics.

03

Conditions studied

  • Mitral Regurgitation

Keywords

  • mitral regurgitation
  • transcatheter edge-to-edge repair
  • artificial intelligence
  • semantic segmentation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients with degenerative or functional mitral regurgitation who underwent Transcatheter Mitral Edge-to-Edge Repair (TEER) with the MitraClip device at multiple participating high-volume structural heart centers. All data are derived from routine clinical care, including intraprocedural transesophageal echocardiographic (TEE) imaging and corresponding clinical records. Only patients with appropriate consent for research use of their data, as defined by the policy of each participating center, are included. The cohort reflects real-world TEER practice across diverse imaging environments, operator experience, and patient anatomies, supporting the development and validation of artificial intelligence-based segmentation and measurement tools with improved generalizability.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years of age) at the time of the index procedure
  • Confirmed diagnosis of degenerative or functional mitral regurgitation
  • Underwent Transcatheter Mitral Edge-to-Edge Repair (TEER) with the MitraClip device at one of the participating centers
  • Intraprocedural transesophageal echocardiographic (TEE) imaging available, complete, and of sufficient quality to support semantic segmentation and real-time measurement analyses
  • Appropriate consent for research use of clinical and imaging data, as per the policy of each participating center

Exclusion criteria

Exclusion Criteria:

  • Incomplete or poor-quality intraprocedural TEE imaging unsuitable for accurate segmentation and measurement
  • Ambiguous or unconfirmed diagnosis of mitral regurgitation
  • Documented refusal to allow use of clinical or imaging data for research purposes
  • Missing essential clinical documentation required to confirm eligibility
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Accuracy of AI-based semantic segmentation of mitral valve leaflets and MitraClip device components

    The accuracy of the deep learning model in segmenting the anterior and posterior mitral leaflets, MitraClip grippers, and clip arms on intraprocedural transesophageal echocardiography (TEE) images. Performance is benchmarked against manual annotations provided by experienced echocardiographers and quantified using the Dice similarity coefficient, sensitivity, and specificity. Target performance: ≥ 90%.

    Time frame: Intraprocedural (TEE images acquired during the TEER procedure)

  2. Accuracy of automated real-time recognition of mitral leaflet insertion length

    The accuracy of the automated measurement system in recognizing the insertion length of the anterior and posterior mitral leaflets in two-dimensional TEE planes during the leaflet grasping process. Algorithm output is compared with manual measurements performed by experienced echocardiographers. Target performance: ≥ 95%.

    Time frame: Intraprocedural (TEE images acquired during the TEER procedure)

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. All clinical and imaging data are pseudonymized and stored under restricted access in accordance with the approved study protocol, applicable data protection regulations (Swiss Human Research Act, Swiss Federal Act on Data Protection, and applicable regulations at each participating center), and the sponsor's data governance policy. Aggregated and anonymized results will be disseminated through peer-reviewed publications and scientific presentations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 8, 2026
StartActual
Sep 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Aug 31, 2030
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07632794
Lead sponsor
Mi Chen
Collaborators
Chinese Academy of Medical Sciences, Fuwai Hospital, San Raffaele University Hospital, Italy, ETH Zurich (Switzerland), Ospedale San Donato
Responsible party
Mi Chen (Dr., HerzZentrum Hirslanden Zürich) — Sponsor-investigator
First posted
Jun 8, 2026
Start date
Sep 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Jun 8, 2026

Study contacts

Mi Chen, MD, PhD
principal investigator · HerzZentrum Hirslanden Zürich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion